Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease

Capital Medical University logo

Capital Medical University

Status

Completed

Conditions

Meniere Disease

Treatments

Other: Transcutaneous Auricular Vagus Nerve Stimulation with Betahistine

Study type

Interventional

Funder types

Other

Identifiers

NCT05328895
taVNS-MD-2022

Details and patient eligibility

About

Objective: To evaluate the effect of Transcutaneous auricular vagus nerve stimulation for the patients Meniere disease. Methods: We enrolled 88 patients at Beijing TongRen Hospital. All treatments were self-administered by the patients at home after training at the hospital. Patients completed questionnaires at baseline and after 4 weeks, 8 weeks, 12 weeks. Tinnitus Handicap Inventory (THI), Dizziness Handicap Inventory (DHI), Pure Tone Audiometry, visual scale of ear stuffiness and SF-36 were performed to evaluate the therapeutic effects. A difference of P \< 0.05 was considered statistically significant.

Enrollment

92 patients

Sex

All

Ages

20 to 61 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age >=18 and Age <=70.
  2. Clinical diagnosis of meniere disease.

Exclusion criteria

  1. History of depression, tumors, thyroid disease, diabetes, cardiac diseases.
  2. History of Otorhinolaryngology surgery.
  3. Pregnant or lactating women.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

92 participants in 2 patient groups, including a placebo group

taVNS group
Experimental group
Description:
taVNS was applied using a Huatuo stimulator (SDZIIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily. The two electrodes were placed on the cymba conchae and concha around the left ear. Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
Treatment:
Other: Transcutaneous Auricular Vagus Nerve Stimulation with Betahistine
Control Group
Placebo Comparator group
Description:
tnVNS was applied using a Huatuo stimulator (SDZIIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily. The two electrodes were placed on the antihelix around the left ear. Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
Treatment:
Other: Transcutaneous Auricular Vagus Nerve Stimulation with Betahistine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems